PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2017 April; 61(4): e02634-16.
Published online 2017 March 24. Prepublished online 2017 January 17. doi:  10.1128/AAC.02634-16
PMCID: PMC5365710

Large-Scale Evaluation of In Vitro Amphotericin B, Triazole, and Echinocandin Activity against Coccidioides Species from U.S. Institutions

ABSTRACT

Large-scale testing of Coccidioides isolates has not been performed, and the frequency of clinical isolates with elevated amphotericin B or triazole MICs has not been evaluated. Coccidioides isolates (n = 581) underwent antifungal susceptibility testing. Elevated MIC values were observed for fluconazole (≥16 μg/ml, 37.3% of isolates; ≥32 μg/ml, 7.9% of isolates), itraconazole (≥2 μg/ml, 1.0% of isolates), posaconazole (≥1 μg/ml, 1.0% of isolates), and voriconazole (≥2 μg/ml, 1.2% of isolates). However, mold-active triazoles exhibited low MICs for the majority of isolates tested. Additional correlation with patient outcomes to determine the relevance of elevated MICs in Coccidioides isolates is needed.

KEYWORDS: Coccidioides, coccidioidomycosis, fluconazole, itraconazole, posaconazole, voriconazole, amphotericin B, flucytosine, caspofungin, antifungal susceptibility testing, endemic mycoses

TEXT

Coccidioidomycosis is an invasive fungal infection caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. Clinical manifestations vary depending on the extent of infection and the immune status of the host. Treatment of patients with coccidioidomycosis has largely consisted of therapy with amphotericin B formulations for those with severe disease or a triazole, most commonly fluconazole, for those with mild to moderate disease (1).

(This work was presented in part at ASM Microbe, Boston, MA, 2016 [2].)

Despite the significant clinical impact of this infection, large-scale susceptibility studies have not been presented. Previous reports observed fluconazole MICs and minimum fungicidal concentrations (MFCs) that exceeded achievable blood levels with ordinary dosing regimens (3, 4). However, the epidemiology and mechanism(s) of resistance in such isolates, and which alternative agents maintain in vitro activity when these isolates are encountered, have not been determined (5).

We assessed the susceptibility profile of a large collection of Coccidioides isolates received by the Fungus Testing Laboratory (University of Texas Health Science Center at San Antonio) between 2001 and 2015. During this period, 581 clinical Coccidioides isolates were received from disparate geographic origins within North America, and susceptibility testing was performed when they were received. Most of the isolates were from California, Arizona, and Texas. Susceptibility testing was performed by broth macrodilution according to the CLSI M38-A2 reference standard as previously described (6,11). MICs were read as the lowest concentration that resulted in ≥80% inhibition of growth compared with the drug-free control. Differences in the geometric mean (GM) MIC values were assessed for significance by analysis of variance (ANOVA) using Tukey's posttest for multiple comparisons.

Voriconazole was the most potent antifungal agent tested, with a GM MIC of 0.107 μg/ml, which was significantly lower than the GM MIC of fluconazole (7.710 μg/ml), itraconazole (0.245 μg/ml), and amphotericin B (0.247 μg/ml) (P < 0.05 for all comparisons) (Table 1). Posaconazole GM MICs (0.141 μg/ml) were similar to those of voriconazole and were significantly lower than those of fluconazole, itraconazole, and amphotericin B (P < 0.0001). The differences between posaconazole and voriconazole GM MICs were not significant (P = 0.98).

TABLE 1
Results of susceptibility testing

The MIC ranges for each antifungal were wide (Table 2). The MIC50 for fluconazole was 8 μg/ml, and the MIC90 was 16 μg/ml; more than one-third (215/581, 37.3%) of isolates exhibited fluconazole MICs of ≥16 μg/ml. Furthermore, 22 isolates (22/581, 3.8%) were identified that had fluconazole MICs of ≥64 μg/ml. Elevated MICs for the mold-active triazoles and amphotericin B were uncommon: itraconazole, ≥2 μg/ml (5/486, 1.0%); posaconazole, ≥1 μg/ml (4/377, 1.1%); voriconazole, ≥2 μg/ml (12/499, 1.2%); and amphotericin B, ≥2 μg/ml (11/397, 2.8%).

TABLE 2
Number of MIC values for each antifungal agent tested at specific concentrations

These results illustrate the relative frequency of elevated fluconazole MICs encountered in clinical Coccidioides isolates and the in vitro superiority of newer mold-active triazoles. Our results are consistent with those of prior studies of Coccidioides in vitro susceptibility (4, 12,14). In all of these smaller studies, fluconazole was less active than comparator antifungals, yet the conclusions of the studies were limited by the relatively low numbers of isolates assessed.

Fluconazole is the most frequently prescribed antifungal medication for the treatment of coccidioidomycosis and is considered first-line therapy for the majority of coccidioidal infections (1). Despite the lack of large-scale susceptibility studies, clinical experience suggests that higher fluconazole doses are often needed for a clinical response to be observed, and doses of 800 mg for primary infection are now routinely recommended by some experts (1).

Together, our results and those of the earlier studies suggest that the in vitro MICs of Coccidioides are similar to those of Histoplasma and Blastomyces, mycoses for which fluconazole is not the suggested first-line option (15, 16). Our in vitro data provide additional support for the higher fluconazole doses often recommended in the treatment of coccidioidomycosis.

The mold-active triazoles, compared with fluconazole, have favorable in vitro activity against Coccidioides spp. However, the in vivo impact of these findings has yet to be determined. Clinical evaluation of these agents in coccidioidomycosis has consisted almost exclusively of salvage studies (17, 18), with the exception of a single comparative clinical trial (19). In this study, fluconazole (400 mg/day) was directly compared with itraconazole (200 mg twice daily). By 12 months, 57% of patients responded to fluconazole, whereas 72% responded to itraconazole (P = 0.05), with relapses reported to be more frequent in the fluconazole-treated group. It remains to be seen if pharmacokinetic and pharmacodynamic parameters are predictive of success in coccidioidomycosis; however, additional investigation is clearly warranted.

Interestingly, we found significant variability in the echinocandin MICs and differences among the three agents. The caspofungin GM MIC (0.188 μg/ml) was higher than those of anidulafungin (0.114 μg/ml) and micafungin (0.089 μg/ml) (P = 0.008). The MIC90 value for caspofungin (8 μg/ml) was also higher than those found for anidulafungin and micafungin (0.25 and 0.125 μg/ml, respectively). This is in contrast to prior in vitro reports suggesting that echinocandins have limited in vitro activity against Coccidioides spp. (4, 13, 20, 21). These earlier in vitro findings are also in contrast to more recent findings of echinocandin in vivo activity in murine and human studies of coccidioidomycosis (22,24).

Our study, which evaluated a large number of clinical Coccidioides isolates, found a wide range of echinocandin MICs and, combined with more recent clinical reports, suggests that this class may exhibit efficacy in the treatment of coccidioidomycosis. However, given the variable susceptibility, echinocandins should not be used as monotherapy. Additionally, we report for the first time, to our knowledge, the distribution of triazole MICs likely to be encountered during the care of patients with coccidioidomycosis. We commonly found elevated fluconazole MICs, with very high MICs (≥64 μg/ml) in a number of isolates. The majority of these isolates retained comparatively low MICs to other triazoles, suggesting that they may be alternative treatment options, pending further study. The lack of patient data associated with the isolates tested is a significant limitation, and the current data set may be biased in that susceptibility testing was requested only for patients who failed therapy. Additionally, species-specific differences were not examined in this study and should be evaluated. Future work focusing on outcomes in patients with infection from isolates with elevated MICs and the molecular mechanisms responsible for in vitro resistance should also be performed.

ACKNOWLEDGMENTS

This study was performed using existing departmental funds.

G.R.T. has received research support from Astellas, Merck, Wako, Cidara and Scynexis. N.P.W. has received research support from Astellas, bioMérieux, Merck, Pfizer, Revolution Medicines, and Viamet.

REFERENCES

1. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, Johnson RH, Kusne S, Lisse J, MacDonald JD, Meyerson SL, Raksin PB, Siever J, Stevens DA, Sunenshine R, Theodore N 2016. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis 63:e112–146. doi:.10.1093/cid/ciw360 [PubMed] [Cross Ref]
2. Thompson GR III, Barker BM, Wiederhold NP 2016. ASM Microbe, 16 to 20 June 2016, Boston, MA, abstr. 300.
3. Stevens DA, Aristizabal BH 1997. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole. Diagn Microbiol Infect Dis 29:103–106. doi:.10.1016/S0732-8893(97)00104-1 [PubMed] [Cross Ref]
4. Ramani R, Chaturvedi V 2007. Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and non-endemic areas. Mycopathologia 163:315–319. doi:.10.1007/s11046-007-9018-7 [PubMed] [Cross Ref]
5. Thompson GR III, Stevens DA, Clemons KV, Fierer J, Johnson RH, Sykes J, Rutherford G, Peterson M, Taylor JW, Chaturvedi V 2014. Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease. Mycopathologia. doi:.10.1007/s11046-014-9816-7 [PubMed] [Cross Ref]
6. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard—2nd ed. CLSI document M38A2 Clinical and Laboratory Standards Institute, Wayne, PA.
7. Shubitz LF, Trinh HT, Galgiani JN, Lewis ML, Fothergill AW, Wiederhold NP, Barker BM, Lewis ER, Doyle AL, Hoekstra WJ, Schotzinger RJ, Garvey EP 2015. Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models. Antimicrob Agents Chemother 59:7249–7254. doi:.10.1128/AAC.00593-15 [PMC free article] [PubMed] [Cross Ref]
8. Kriesel JD, Sutton DA, Schulman S, Fothergill AW, Rinaldi MG 2008. Persistent pulmonary infection with an azole-resistant Coccidioides species. Med Mycol 46:607–610. doi:.10.1080/13693780802140923 [PubMed] [Cross Ref]
9. Shubitz LF, Galgiani JN, Tian ZQ, Zhong Z, Timmermans P, Katz L 2006. Efficacy of ambruticin analogs in a murine model of coccidioidomycosis. Antimicrob Agents Chemother 50:3467–3469. doi:.10.1128/AAC.00670-06 [PMC free article] [PubMed] [Cross Ref]
10. Clemons KV, Homola ME, Stevens DA 1995. Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo. Antimicrob Agents Chemother 39:1169–1172. doi:.10.1128/AAC.39.5.1169 [PMC free article] [PubMed] [Cross Ref]
11. Clemons KV, Stevens DA 1997. Efficacies of two novel azole derivatives each containing a morpholine ring, UR-9746 and UR-9751, against systemic murine coccidioidomycosis. Antimicrob Agents Chemother 41:200–203. [PMC free article] [PubMed]
12. Gonzalez GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D 2005. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 43:281–284. doi:.10.1080/13693780500088416 [PubMed] [Cross Ref]
13. Cordeiro RA, Brilhante RS, Rocha MF, Fechine MA, Costa AK, Camargo ZP, Sidrim JJ 2006. In vitro activities of caspofungin, amphotericin B and azoles against Coccidioides posadasii strains from Northeast Brazil. Mycopathologia 161:21–26. doi:.10.1007/s11046-005-0177-0 [PubMed] [Cross Ref]
14. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR 2000. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 44:1734–1736. doi:.10.1128/AAC.44.6.1734-1736.2000 [PMC free article] [PubMed] [Cross Ref]
15. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, Infectious Diseases Society of America. 2007. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 45:807–825. doi:.10.1086/521259 [PubMed] [Cross Ref]
16. Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA, Infectious Diseases Society of America. 2008. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 46:1801–1812. doi:.10.1086/588300 [PubMed] [Cross Ref]
17. Stevens DA, Rendon A, Gaona-Flores V, Catanzaro A, Anstead GM, Pedicone L, Graybill JR 2007. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 132:952–958. doi:.10.1378/chest.07-0114 [PubMed] [Cross Ref]
18. Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE 2011. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 53:1060–1066. doi:.10.1093/cid/cir642 [PubMed] [Cross Ref]
19. Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, Mirels LF, Nassar F, Lutz JE, Stevens DA, Sharkey PK, Singh VR, Larsen RA, Delgado KL, Flanigan C, Rinaldi MG 2000. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial: Mycoses Study Group. Ann Intern Med 133:676–686. doi:.10.7326/0003-4819-133-9-200011070-00009 [PubMed] [Cross Ref]
20. Stevens DA. 2000. Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother 44:2547–2548. doi:.10.1128/AAC.44.9.2547-2548.2000 [PMC free article] [PubMed] [Cross Ref]
21. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M 2003. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 47:1376–1381. doi:.10.1128/AAC.47.4.1376-1381.2003 [PMC free article] [PubMed] [Cross Ref]
22. Gonzalez GM, Tijerina R, Najvar LK, Bocanegra R, Luther M, Rinaldi MG, Graybill JR 2001. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 45:1854–1859. doi:.10.1128/AAC.45.6.1854-1859.2001 [PMC free article] [PubMed] [Cross Ref]
23. Gonzalez GM, Gonzalez G, Najvar LK, Graybill JR 2007. Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model. J Antimicrob Chemother 60:1341–1346. doi:.10.1093/jac/dkm383 [PubMed] [Cross Ref]
24. Levy ER, McCarty JM, Shane AL, Weintrub PS 2013. Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: a retrospective case series. Clin Infect Dis 56:1573–1578. doi:.10.1093/cid/cit113 [PubMed] [Cross Ref]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)